Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Hiroaki Shimmura et al.|Journal of Geriatric Oncology|2025Cited by 1
MP28-10 IMPACT OF CYTOREDUCTIVE NEPHRECTOMY ON IMMUNE CHECKPOINT INHIBITOR THERAPY: TREATMENT OUTCOMES OF IMMUNE INHIBITORS COMBINATION THERAPIES FOR METASTATIC RENAL CELL CARCINOMA WITH PRIMARY KIDNEY TUMORSToshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida et al.|The Journal of Urology|2025Cited by 0
Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Research Square|2025Cited by 0
Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Anticancer Research|2025Cited by 0